A Prospective, Multicenter, Single-Arm Clinical Study Evaluating the Safety and Effectiveness of The Tixel Fractional System in The Treatment of Periorbital Wrinkles
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Novoxel Ltd.
- 入组人数
- 51
- 试验地点
- 5
- 主要终点
- Percentage of Participants With Safety Adverse Events
研究概览
简要总结
A Prospective, Multicenter, Single-Arm Clinical Study of 51 study subjects who are seeking a procedure to reduce the appearance of the peri-orbital wrinkles. Up to 5 investigational centers in Israel and the United States will participate in the recruitment. Each study subject will receive four (4) treatments with Tixel in a monthly interval. Follow-up will occur 1 month and 3 months following last treatment.
详细描述
A Prospective, Multicenter, Single-Arm Clinical Study of 51 subjects who are seeking a procedure to reduce the appearance of the periorbital wrinkles, and meet study eligibility criteria, and have provided informed consent will be enrolled in the study. Up to 5 investigational centers in Israel and the United States will participate in the recruitment. Each study subject will receive 4 treatments with Tixel in a monthly interval. Follow-up will occur at 1 month and 3 months following the last treatment.
The clinic visits will be as follow:
- Baseline (1st tx)
- Phone-call visit (3 days after the first treatment)
- 4wk (2nd tx)
- 8wk (3rd tx)
- 12wk (4th tx)
- 4 weeks after the last treatment (1st FU)
- 12 weeks after the last treatment (2nd FU= 3 months FU, primary endpoint and study completion visit) Primary Efficacy Endpoint is the comparison of the proportion of subjects with a ≥ 1-score improvement on the FWCS at the 3-month visit compared to baseline as determined by at least 2 out of 3 blinded Independent Photographic Reviewers.
Primary Safety Endpoint is the evaluation of related adverse events up to the 3-month visit after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Blinded assessed of the improvement would be done between Last FU images and baseline, following randomization of the images.
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female 35-70 years old diagnosed with clinically evident fine (mild) to moderate depth periorbital wrinkling
- •Willingness and ability to comply with all required study activities including returning for follow-up visits and protocol requirements.
- •The subject is able to provide written informed consent and perform the study's activities according to HIPAA guidelines and/or Israeli law, depending on each specific study site.
- •Fitzpatrick wrinkle score of 3-7 in the peri-orbital areas per the treating investigator and clinically noticeable wrinkles in the treating area.
- •Stable body weight during the study period.
- •Skin Type I - V as per Fitzpatrick Skin Scale
排除标准
- •Past treatment with Tixel device.
- •The subject may not undergo treatment by the Tixel device according to the device's contra-indications for use, as defined in the User Manual and in the Instructions for Use and by any other labeling of the device.
- •Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
- •Female subjects who are pregnant, or planning to become pregnant, or have given birth less than 3 months ago or are lactating.
- •Subjects with significant exposure to critical amounts of ultraviolet light (Sun-tan).
- •Subjects who have had the following treatments:
- •a cosmetic procedure to improve peri-orbital rhytides (i.e. periorbital or eyelid/eyebrow surgery, brow lift, CO2/Erbium/similar laser/fractional resurfacing, radiofrequency treatment) within 12 months
- •prior facial treatments with laser, surgical, chemical or light-based facial treatments within the previous 12 months, over the periorbital area including botulinum toxin injections, microdermabrasion or prescription level glycolic acid treatments.
- •Injectable filler in cheeks (mid face) temples and in the upper face area to be treated within 12 months of investigation.
- •Any subject who have visible scars or other visible changes over the treated areas that may affect evaluation of response and/or quality of photography.
- •Subjects with any type of active cut, wound, inflammation, lesion (benign, premalignant or malignant) or active bacterial, viral, fungal, or herpetic infection on the skin on the designated treatment sites or in close proximity to it.
- •Existing or history of the following (when discussing skin conditions, refers only to the periorbital sites):
- •skin malignancy, or any diagnosis of suspected malignancy
- •Collagen or vascular or bleeding disease
- •Immunosuppression or autoimmune disease
- •Erythema with or without blistering
- •History of post inflammatory hyperpigmentation.
- •Active Acne Vulgaris, HSV-1, or any existing skin condition/disease that in the investigator's opinion would interfere with the evaluation of the safety of the study treatment and evaluation.
- •Any skin pathology which can induce bullous lesions, urticaria, or demonstrate a Koebner phenomenon (psoriasis, lichen planus, etc.).
- •Any disease that inhibits pain sensation
- •History of keloid formation, or hypertrophic scarring
- •Conditions affecting healing rate (i.e. diabetes mellitus I or II, vascular condition, etc.)
- •neuromuscular disorders
- •Subjects who have used, within 30 days, any medication that can cause dermal hypersensitivity or affect skin characteristics over the treated area (i.e. topically applied Retinoids, Hydroquinone, Chemical peel of any strength: glycolic acid, lactic acid, salicylic acid)
- •Subjects who have used, systemic treatment which may induce dyspigmentation, such as amiodarone, clofazinmine, minocycline or chloroquine.
- •Subjects currently taking or have taken an oral retinoid in the past six months; Subjects currently taking long-term oral steroid treatment.
- •Concurrent therapy that, in the principal investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment.
- •Subjects who anticipate the need for major surgery or overnight hospitalization during the study that can affect the study schedule or treatment evaluation.
- •Enrollment in any active study involving the use of investigational devices or drugs.
- •Any other cause per the principal investigator's discretion.
研究组 & 干预措施
Tixel 2
Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject would be questioned about pain level, subjective dountime assessment and subjective response assessment. Images would be taken at baseline and in Follow-Up visits
干预措施: Tixel 2 (Device)
结局指标
主要结局
Percentage of Participants With Safety Adverse Events
时间窗: 6 months
Evaluation of related adverse events up to the 3-month after a treatment visit.
The Mean Improvement and Treatment Effectiveness by Blinded Assessors Using Using the Fitzpatrick Wrinkle Classification Scale (FWCS) Evaluation
时间窗: baseline and at 3 months
Comparison of the proportion of subjects with a ≥ 1-score improvement on the Fitzpatrick Wrinkle Classification Scale (FWCS) at the 3-month visit compared to baseline as determined by at least 2 out of 3 blinded Independent Photographic Reviewers. The FWCS is a clinically validated assessment tool used to assess skin wrinkle severity and elastosis on a scale from 1 through 9, where the lower score is considered better.
次要结局
- Satisfaction Questionnaire(up to 6 months)
- The Mean Score Evaluation of the Pain and Discomfort for Each Treatment(Up to 6 months)
- The Mean Evaluation of Improvement Assessed by the Handling Physician by Using GAIS Scale - Global Aesthetic Improvement Scale Assessment(Baseline and 3 months visits)